Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute

Seattle Genetics is looking for a quicker path to resolution with Daiichi Sankyo over antibody drug conjugate technology that both companies claim ownership of. Seattle Genetics is pushing for arbitration and also filed a motion to dismiss Daiichi Sankyo’s lawsuit that was initiated last month.